Surface Glycan Shielding Service for Extended CAR-T Support Circulation

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Despite the clinical success of CAR-T therapy, challenges remain in poor cell persistence, rapid immune-mediated clearance, and suboptimal in vivo expansion that limit sustained antitumor efficacy. Creative Biolabs' Surface Glycan Shielding platform addresses these barriers by equipping CAR-T cells with a protective glycan layer that reduces immune recognition while preserving full functionality. We offer a tailored engineering service to integrate glycan shielding onto patient-derived or allogeneic CAR-T products under optimized, regulatory-compliant protocols. This approach significantly extends circulatory persistence, minimizes infusion-related cell loss, and provides our clients with a robust, scalable solution to enhance therapeutic durability and improve clinical outcomes.

Introduction

Surface Glycan Shielding is a precision engineering strategy that induces hyperglycosylation on CAR-T cells via specific gene knockout, creating a physical barrier that masks immunogenic epitopes without compromising effector function. This approach enables extended circulatory persistence by shielding allogeneic CAR-T cells from host T-cell and NK-cell-mediated clearance, thereby supporting sustained antitumor activity and off-the-shelf feasibility.

Fig.1 Glycan shield platform for improved CAR-T retention and function. (Creative Biolabs Original) Fig.1 Glycan-based immune shielding for prolonged CAR-T persistence.

Our Service

Creative Biolabs offers a full array of strategies to conceal therapeutic T-cells from host immune detection while preserving their full anti-tumor capacity. By systematically expanding the cellular glycan landscape, our platform addresses the challenge of immune rejection in off-the-shelf CAR-T development, sterically blocking host antibodies and T-cell receptors from accessing the graft.

What We Can Offer

Our platform leverages SPPL3 knockout to engineer allogeneic CAR-T cells with a protective glycan shield, enabling persistent in vivo function without immunosuppressive preconditioning, supported by comprehensive characterization and validation services.

Featured services of precision CAR-protein enrichment & exosomal sorting technology at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

The specific CAR-T construct sequence or viral vector.
Baseline phenotypic data of the target T-cell population.
Specific host-rejection profiles if available.

Key Steps:

Workflow of precision CAR-protein enrichment & exosomal sorting technology at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables: You will be provided with a comprehensive analytical characterization summary, accompanying functional potency data, and the final engineered exosome preparation.

Key Advantages

Mitigated T-Cell Exhaustion: The shielding layer reduces tonic signaling and excessive antigen-independent activation, preserving a less differentiated, more functional phenotype that resists terminal exhaustion.
Enhanced Tumor Infiltration: Reversible glycan shielding can be designed to shed upon encountering the tumor microenvironment, allowing temporary protection during trafficking without compromising eventual homing and infiltration into tumor sites.
Controlled On-Target Off-Tumor Toxicity: Conditional removal of the glycan shield enables localized CAR-T activation, minimizing damage to healthy tissues that express the target antigen.

FAQs

Q1: Does glycan shielding interfere with the CAR's ability to bind to tumor antigens?

A1: We employ GLYCO simulations to ensure the shielding remains selective. By precisely mapping the CAR's antigen-binding pocket, we tailor glycan density to effectively evade immune detection while avoiding any steric obstruction at the recognition interface, preserving full tumor-targeting functionality.

Q2: How does SPPL3 deletion differ from traditional HLA-knockout?

A2: Conventional HLA knockout renders cells "invisible" to T cells but often triggers NK-cell "missing-self" rejection. In contrast, SPPL3-mediated shielding masks a broader array of surface ligands, including HLA, thereby simultaneously reducing recognition by both T cells and NK cells, offering a more comprehensive immune evasion strategy without compromising cell fitness.

Why Choose Us

At the glyco-immune interface, we bridge rational design with biological execution. Our integrated pipeline transforms shielding concepts into stable, functional CAR-T products, while SPPL3 deletion enables fitter allogeneic platforms by preserving endogenous TCR without compromising cell fitness, delivering both persistence and biological fidelity.

Customer Reviews

"Applying Creative Biolabs' surface glycan shielding platform enabled robust stabilization of our CAR constructs. The high-resolution GLYCO reports precisely pinpointed areas of shield failure—an unprecedented level of detail." Dr. A**n L.

"SPPL3 knockout via Creative Biolabs markedly extended CAR-T circulation in NHP models. Where rapid clearance once hindered our progress, this stealth modification proved transformative." Prof. M**o R.

"The genetic shielding approach from Creative Biolabs delivered superior consistency over conventional enzymatic methods. It streamlined manufacturing while strengthening the safety profile of our allogeneic candidates." Dr. J**e S.

How to contact us?

Creative Biolabs delivers a next-generation Surface Glycan Shielding platform designed to advance off-the-shelf cell therapies with improved circulatory persistence and lower immunogenicity. Through precision GLYCO mapping and SPPL3-based engineering, we offer effective strategies to counter host immune rejection. For project inquiries or customized proposals, please contact our scientific team.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.